Michigan Quality Improvement Consortium Clinical Practice Guideline Update Alert

Guideline: Management of Type 2 Diabetes Mellitus

Released: June 2022

This alert provides a summary of only the recommendations which were updated. Refer to the complete guideline for all recommendations and level of evidence.

Updated recommendations include:

Assessment

- Deleted: “gradual” as a qualifier before “weight loss”
- Added: “obese” to verbiage. Now states “Goal for overweight/obese patients…”
- Added: Links for “Calculate ASCVD risk”, “treatment algorithm”

A1c Goals

- Added: verbiage to indicate “individualized goal…”

Social Determinants of Health

- Added: “and health insurance status”

Additional assessment and interventions:

- Deleted: Blood Pressure control – covered elsewhere in document
- Revised: verbiage for Chronic Kidney Disease
- Added: eye exams “at least” annually
- Revised: Foot care verbiage from “foot exam” to “inspect feet”
- Added: COVID-19 to immunizations
- Revised: for Non-alcoholic steatohepatitis to add consider…”and ultrasound”, changed “exercise” to “physical activity

Weight Loss

- Changed: verbiage from “Weight loss” to “Weight Management” in title and in body of section, and several other changes made to verbiage

Hypertension Control

- Moved: “Refer to treatment algorithm for patients with diabetes” from Blood pressure section toward top to this section toward bottom

Glycemic Control

- Revised: verbiage related to Metformin
- Added: “Consider CGM for patients treated with multiple daily injections of insulin or insulin pump who adjust doses and/or have histories of severe hypoglycemia”